Brigatinib Tablet Market Size, Share, and Growth Analysis, By Strength (30 mg, 90 mg), By Indication (ALK-Positive NSCLC, Other Oncology Indications), By Distribution Channel, By End User, By Region - Industry Forecast 2026-2033

Global Brigatinib Tablet Market size was valued at USD 780.0 Million in 2024 and is poised to grow from USD 843.18 Million in 2025 to USD 1572.27 Million by 2033, growing at a CAGR of 8.1% during the forecast period (2026-2033).

The global market for brigatinib tablets is characterized by the oral ALK inhibitor's role in addressing treatment-resistant non-small cell lung cancer (NSCLC), particularly for patients who do not respond to first-generation therapies such as crizotinib. A major growth driver is the demand for effective second-line treatment options, as brigatinib offers enhanced central-brain penetration and extended progression-free survival rates. This has led to increased prescriptions globally, driven by positive trial results that influenced insurance coverage and clinical pathways. Additionally, the rising incidence of ALK-rearranged lung cancer among younger, non-smoking populations amplifies the need for accessible oral therapies. Collaborations between pharmaceutical companies and generic manufacturers are aimed at reducing costs, thus facilitating greater market adoption, particularly in emerging markets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Brigatinib Tablet market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Brigatinib Tablet Market Segments Analysis

Global brigatinib tablet market is segmented by strength, indication, distribution channel, end user and region. Based on strength, the market is segmented into 30 mg, 90 mg and 180 mg. Based on indication, the market is segmented into ALK-Positive NSCLC and Other Oncology Indications. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Cancer Centers and Specialty Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Brigatinib Tablet Market

The expansion of brigatinib's indications for treating ALK-positive and ROS1-positive non-small cell lung cancer significantly enhances its therapeutic potential, encouraging oncologists to incorporate it earlier in treatment protocols. This widened scope leads to increased prescribing rates as healthcare professionals look for effective solutions to combat resistance mechanisms. The rising adoption of this medication across hospitals, specialty pharmacies, and outpatient clinics is driving market demand. Additionally, awareness initiatives from pharmaceutical companies bolster confidence among prescribers, promoting sustained growth. Patient advocacy organizations also highlight the drug's favorable safety profile, further facilitating its integration into standard treatment practices.

Restraints in the Global Brigatinib Tablet Market

The high cost of brigatinib compared to standard chemotherapy options imposes financial constraints on hospitals and insurance companies, resulting in more stringent formulary placements and necessitating prior authorization processes. Payers frequently negotiate limited reimbursement terms, which can hinder or restrict patient access, particularly in areas with limited healthcare budgets. This circumstance leads physicians to consider more cost-effective alternatives, thereby decreasing prescription rates and hampering the drug's market penetration despite its clinical benefits. As a result, the financial barriers associated with brigatinib serve as a considerable obstacle to its widespread acceptance, particularly in burgeoning markets.

Market Trends of the Global Brigatinib Tablet Market

The Global Brigatinib Tablet market is witnessing a significant trend towards precision oncology, fueled by the integration of comprehensive genomic profiling into treatment protocols. This paradigm shift emphasizes the need for therapies tailored to specific ALK and ROS1 mutations, driving an increased demand for companion diagnostics and fostering strategic collaborations between pharmaceutical companies and diagnostic providers. As healthcare systems focus on mutation-driven treatment algorithms, investments in data infrastructure are emerging to facilitate real-time decision-making, which in turn enhances patient access to targeted brigatinib regimens. This trend solidifies brigatinib's role in personalized lung cancer care pathways across the globe.